Core Viewpoint - Telo Genomics Corp. is conducting a non-brokered private placement offering of secured convertible debentures for gross proceeds of up to $1,200,000 to fund lab trials and general working capital [1][3]. Group 1: Offering Details - The debentures will have an interest rate of 15% per annum, compounded quarterly, and will mature 9 months after the closing date [2]. - Holders of the debentures can convert them into common shares at a conversion price of $0.05 per share before the maturity date [2]. - For every $100,000 of convertible debentures issued, Telo Genomics will issue 2 million detachable warrants, each exercisable at $0.08 per share for 12 months [2]. Group 2: Use of Proceeds - Proceeds from the offering are expected to be allocated for lab trials and general working capital [3]. Group 3: Company Overview - Telo Genomics is a biotech company specializing in a comprehensive telomere platform with applications in oncology and neurological diseases, focusing on liquid biopsies [4]. - The company combines expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to develop diagnostic products [4]. - Telo Genomics has substantiated its technology through over 160 peer-reviewed publications and 30+ clinical studies involving more than 3,000 patients [4].
Telo Genomics Announces Non-Brokered Private Placement of Convertible Debentures for up to $1,200,000